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The aim of this study was to determine the tolerability and efficacy of two oral regimens of levetiracetam, 1000 mg and 2000 mg
twice daily, as add-on treatment without titration in patients with refractory epilepsy.
After a 1- to 4-week baseline, 119 patients were randomized to receive levetiracetam 2000 mg daily, 4000 mg daily, or
placebo for a 24-week double-blind period, then levetiracetam 4000 mg daily in a 24-week open-label phase.
Somnolence was the most common reason for discontinuation, and along with asthenia, occurred more frequently with
levetiracetam than placebo. Responder rates were higher with levetiracetam 2000 mg and 4000 mg daily (48.1% [P < 0.05]
and 28.6% [NS], respectively) than placebo (16.1%). In the open-label phase, the overall responder rate was 43.0%. Switching
from placebo to levetiracetam increased the overall responder rate from 16.7% to 44.0%. No such increase was observed with
patients initiated on levetiracetam 2000 mg daily.
Levetiracetam initiated at doses of 2000 mg or 4000 mg daily without titration is well-tolerated and effective as add-on therapy
in patients with partial and/or generalized seizures. The higher dose may be related to an increased incidence of somnolence
and is not necessarily more effective than the lower dose.
c© 2000 BEA Trading Ltd
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INTRODUCTION
Between 30% and 50% of patients with epilepsy ei-
ther fail to respond adequately to, or are unable to
fully comply with, standard antiepileptic therapy1, 2.
Approximately one-third of patients treated with cur-
rently available antiepileptic drugs have seizures that
are refractory to therapy3. In addition, adverse effects
prevent adequate seizure control in a reported 20–
30% of patients taking antiepileptic drugs4. Individu-
alized upward dose titration to an effective dose is one
method employed to avoid unnecessary dose-related
adverse effects5. Currently, antiepileptic drug devel-
opment is focused on providing an agent with a broad
spectrum of antiepileptic activity and with an over-
all improved safety, tolerability, and efficacy profile to
maximize seizure control.
Levetiracetam, an S-enantiomer derivative of pyrro-
lidine acetamide, is a novel agent with a broad-
spectrum effect in animal models of partial and gener-
alized epilepsy6–8. Levetiracetam has both antiepilep-
tic and antiepileptogenic properties6, 8, 9. Although the
mechanism of action of levetiracetam has not been
fully elucidated, the drug does not appear to act at any
recognized site of antiepileptic drug activity. Instead,
in vitro studies suggest a brain-specific binding site10.
Compared with other antiepileptic drugs, leve-
tiracetam has a wide margin of safety. Results of
pre-clinical studies show no evidence for carcino-
genic, mutagenic, or teratogenic potential7. Leve-
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tiracetam has a favourable pharmacokinetic profile
in humans. Following oral administration, levetirac-
etam undergoes rapid and almost complete absorption;
steady-state plasma levels are attained approximately
48 hours after administration. Levetiracetam exhibits
linear kinetics, is minimally protein bound, and has
no effect on hepatic cytochrome P450 enzymes. It is
partly metabolized in blood and fully excreted in urine,
mostly as unchanged drug11.
The clinical effects of levetiracetam have been eval-
uated in three placebo-controlled clinical studies of
patients with epilepsy. In these studies, levetiracetam,
initiated at 1000 mg daily and then increased up to
2000 mg or 3000 mg daily in 1000 mg increments,
effectively reduced the frequency of seizures in pa-
tients with partial seizures12. It was well-tolerated,
and the most commonly reported adverse events, re-
ported for more than 3% of patients and with a dif-
ference of more than 3% between levetiracetam and
placebo, were somnolence, asthenia, and dizziness
(<15% of patients). Single-blind and open-label stud-
ies have shown encouraging results when levetirac-
etam is titrated upward to 4000 mg daily13. The pur-
pose of the present study was to ascertain the tolerabil-
ity and efficacy of levetiracetam at doses of 2000 mg
and 4000 mg daily as add-on therapy in patients with
refractory epilepsy, administered without titration.
PATIENTS AND METHODS
Study population
Eligible patients were men or women between the ages
of 16 and 70 years with well-characterized refractory
epilepsy and any seizure type (partial [type I] or secon-
darily generalized or primary generalized tonic–clonic
seizures [type II]) classified according to the Interna-
tional League Against Epilepsy (ILAE) criteria14. Pa-
tients had to have been maintained on a stable dosage
regimen of up to three antiepileptic drugs for at least
3 months prior to study entry. In addition, they were re-
quired to have experienced at least four seizures in the
24 weeks prior to study entry. Women of childbearing
potential were eligible only if they were using a re-
liable method of contraception. All patients provided
written informed consent prior to enrolment, and the
study was approved by the individual ethical review
procedures of the participating centres.
Patients were excluded if they had a history of al-
lergy, alcohol or drug abuse, a serious medical condi-
tion that could interfere with the assessment of safety
and efficacy, psychotic conditions, problems with ab-
sorption, metabolism, or elimination of drugs, includ-
ing gastrointestinal dysfunction, or renal or hepatic in-
sufficiency.
Study design
This was a multicentre, double-blind, randomized
study with three parallel groups designed to evalu-
ate the tolerability and efficacy of two oral doses of
levetiracetam (2000 mg and 4000 mg daily) as add-
on therapy in patients with refractory epilepsy of any
type. The study was conducted at 37 sites in Belgium
and the United Kingdom between September 1993 and
March 1997. The study consisted of four phases: a
1- to 4-week baseline period, a 24-week double-blind
treatment period, a 24-week open-label treatment pe-
riod, and a 4-week run-out/downtitration period (or
entry into an open follow-up study) (Fig. 1).
Patients were seen at an initial screening visit, and if
eligible, were randomized within 4 weeks (baseline) to
2000 mg daily (1000 mg twice daily) or 4000 mg daily
(2000 mg twice daily) of levetiracetam, or matching
placebo tablets for 24 weeks. Randomization occurred
in blocks of three, defining the treatment numbers per
investigator. In each block, a random procedure (gen-
erated by the RANUNI function of SAS software) per-
formed the permutation of the three treatment num-
bers. Patients in each study centre were assigned treat-
ment numbers according to the number of the coun-
try/principal investigator and the chronological order
of their entry into the study. Levetiracetam was pro-
vided as white 500 mg tablets and placebo as matching
tablets, equal in appearance and taste. Both levetirac-
etam and placebo were supplied by UCB S.A. Pharma
Sector.
The assigned dose was initiated at the start of
active treatment. Visits were scheduled after 4, 12,
and 24 weeks of double-blind treatment. At the end
of this period, seizure-free patients continued on
their assigned dose of levetiracetam for an additional
24 weeks in the open-label treatment period with vis-
its after 12 and 24 weeks. All patients who were not
seizure free at the end of the double-blind treatment
period received 4000 mg daily of levetiracetam (with-
out uptitration) in an open-label fashion. At the fi-
nal visit of the study, levetiracetam was discontinued
abruptly (run-out) or decreased by 1000 mg per week,
or patients entered an open follow-up study. The inves-
tigator could withdraw patients from the study if con-
sent was withdrawn, the double-blind code was bro-
ken, if an adverse event occurred that was considered
by the investigator to require discontinuation, or if the
patient became pregnant.
Measurement of safety and tolerability. The primary
assessment was the tolerability and safety of leve-
tiracetam initiated at high therapeutic doses without
titration. Complete physical and neurological exami-
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Fig. 1: Study design illustrating timeline and components for each period of the study. AED = antiepileptic drug; LEV =
levetiracetam.
nations, haematological and blood chemistry param-
eters, urinalyses, and antiepileptic drug plasma levels
were carried out at each study visit. Adverse events
were recorded in detail and rated by investigators
as mild, moderate, or severe. A causal relationship
to study treatment was assessed by investigators as
highly probable, probable, possible, unlikely, or no re-
lationship.
Measurement of efficacy. Throughout the study, all
patients completed daily record cards on which they
logged the number, duration, description, and date of
each seizure. At each visit, the investigator recorded
the number of seizures and classified each seizure ac-
cording to ILAE criteria. The main efficacy assess-
ment was the responder rate, defined as the proportion
of patients achieving a≥50% reduction in total seizure
frequency after having completed 24 weeks of double-
blind treatment compared with baseline. Other effi-
cacy variables included responder rates after 4 weeks
of double-blind treatment, and seizure frequency by
seizure type and number of seizure-free patients.
Statistical methods
The intention-to-treat population included all random-
ized patients who had received at least one dose of
study medication. The inferential intention-to-treat
population consisted of the set of patients from the
intention-to-treat population who provided data for
the relevant treatment period(s). All treatment com-
parisons were made using two-tailed tests at the 0.05
significance level. The responder rate analyses were
performed by means of logistic regression. Odds ra-
tios for obtaining a 50% seizure reduction and 95%
confidence interval were calculated. Median percent-
age reduction of weekly seizure frequency per seizure
type (I and II) were analysed using the Wilcoxon rank
sum test.
Adverse events were tabulated by body system, pre-
ferred COSTART term, severity, and relationship to
the study drug. The numbers of patients who experi-
enced at least one adverse event were compared using
logistic regression. Baseline and study results of labo-
ratory tests, vital signs, and mean trough antiepilep-
tic drug plasma levels were compared among treat-
ment groups using the Kruskal–Wallis test on differ-
ence from baseline.
RESULTS
Patient demographics
A total of 136 patients were screened; 119 patients
were randomized to double-blind treatment and com-
prised the intention-to-treat population: 39 in the
placebo group, 42 in the group receiving levetiracetam
2000 mg daily, and 38 in the group receiving leve-
tiracetam 4000 mg daily (Fig. 2). Treatment groups
were comparable with respect to baseline character-
istics (Table 1). Across all treatment groups, the mean
age was 38 years, the duration of epilepsy ranged from
0.4 to 57.6 years, and the mean age of epilepsy on-
set was 14.4 years. Median seizure frequency was de-
termined for the set of patients from the intention-to-
treat population who had adequate data (non-missing
and properly completed) at both baseline and follow-
ing randomization. At baseline, it was 1.24 (N = 36),
1.21 (N = 34), and 1.34 (N = 36) per week for the
placebo, 2000 mg daily, and 4000 mg daily treatment
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Fig. 2: Patient disposition. LEV = levetiracetam.
groups, respectively. Sixteen patients were completely
seizure free during the baseline period, and in the ef-
ficacy analysis, these patients were treated as non-
responders. The most common antiepileptic drug reg-
imens at baseline included carbamazepine (N = 69),
valproate (N = 38), phenytoin (N = 37), or pheno-
barbitone (N = 25).
Patient disposition
Among the 119 patients randomized to drug treat-
ment, 33 (placebo, N = 10; levetiracetam 2000 mg
daily, N = 14; levetiracetam 4000 mg daily, N = 9)
discontinued during the double-blind treatment period
(Fig. 2). The number of patients who discontinued was
comparable among treatment groups. Most patients
who discontinued in the first month did so because
of adverse events (Fig. 3). Somnolence was the most
commonly reported reason for study discontinuation.
A total of 86 patients continued into the open-label
treatment period (Table 2).
Safety and tolerability
The incidence of adverse events was similar among
study groups (placebo, 84.6%, 33/39; levetiracetam
2000 mg daily, 83.3%, 35/42; levetiracetam 4000 mg
daily, 84.2%, 32/38). In the double-blind treatment
period, the most frequently reported adverse events
were somnolence and asthenia (COSTART term for
fatigue or tiredness) (Table 3). The incidence of som-
nolence was highest in patients receiving 4000 mg
daily of levetiracetam (44.7%, 17/38), but was com-
parable between the 2000 mg daily treatment group
and placebo (26.2%, 11/42 and 25.6%, 10/39, re-
spectively). Asthenia was most commonly reported by
patients in the 2000 mg daily treatment group (31.0%,
13/42), but was similar between the 4000 mg daily
treatment group and placebo group (13.2%, 5/38 and
15.4%, 6/39, respectively). Other frequently reported
adverse events (≥10% incidence in at least one of
the levetiracetam treatment groups) were accidental
injury (more frequent in the placebo group), infec-
tion, nausea, dizziness, and urinary tract infection. Ad-
verse events generally appeared within the first month
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Table 1: Patient demographics and history of epilepsy (intention-to-treat population).
Levetiracetam Levetiracetam
Placebo 2000 mg/d 4000 mg/d
Variable (N = 39) (N = 42) (N = 38)
Mean age (y) ± SD 35± 12 39± 13 40± 12
Gender, (%) male/female 62/38 69/31 53/47
Mean age at epilepsy onset (y) ± SD 9.3± 9.0 18.3± 14.8 15.4± 13.3
Mean duration of epilepsy (y) ± SD 26.0± 13.2 21.1± 14.4 24.6± 15.6
Unknown aetiology of epilepsy, N (%) 24 (61.5) 29 (69.0) 20 (52.6)
Patients with ≥1 seizure reported over baseline perioda, N (%)
Partial onset (I) 19 (48.7) 20 (47.6) 19 (50.0)
Generalized (II) 16 (41.0) 17 (40.5) 17 (44.7)
All seizures (I+II+III) 32 (82.1) 35 (83.3) 32 (84.2)
SD = standard deviation.
a 16 patients were seizure free during the 4-week baseline period (six in the placebo group; four in the levetiracetam 2000 mg/day group;
six in the levetiracetam 4000 mg/day group; four other patients had missing information).
Table 2: Patient number and reasons for premature discontinuation (intention-to-treat population).
Double-blind period Open-label
Reason for Levetiracetam Levetiracetam Levetiracetam
discontinuation, Placebo 2000 mg 4000 mg 4000 mg
N (%) (N = 39) (N = 42) (N = 38) (N = 86)
Total 10 (25.6) 14 (33.3) 9 (23.7) 8 (9.3)
Adverse events 6 (15.4) 11 (26.2) 5 (13.2) 5 (5.8)
— somnolence 1 (2.6) 5 (11.9) 4 (10.5) 1 (1.2)
Withdrew consent 2 (5.1) 1 (2.4) 2 (5.3) 0 (0)
Othera 2 (5.1) 2 (4.8) 2 (5.3) 3 (3.5)
a Includes protocol violation, lack or loss of efficacy.
Table 3: Most commonly reported adverse events in the
double-blind treatment period (incidence ≥10% in at least
one of the levetiracetam treatment groups) (intention-to-treat
population).
Levetiracetam Levetiracetam
Placebo 2000 mg/d 4000 mg/d
Adverse event (N = 39) (N = 42) (N = 38)
Somnolence 10 (25.6%) 11 (26.2%) 17 (44.7%)
Asthenia 6 (15.4%) 13 (31.0%) 5 (13.2%)
Accidental injury 6 (15.4%) 1 (2.4%) 5 (13.2%)
Infection 3 (7.7%) 1 (2.4%) 6 (15.8%)
Nausea 1 (2.6%) — 5 (13.2%)
Dizziness — 2 (4.8%) 4 (10.5%)
Urinary tract infection 1 (2.6%) — 4 (10.5%)
No significant difference compared with placebo.
of treatment. During the open-label treatment period,
somnolence occurred in 8.1% (N = 7) and asthenia in
3.5% (N = 3) of the 86 patients.
Ten patients reported serious adverse events during
the double-blind period: placebo, N = 3 (7.7%); lev-
etiracetam 2000 mg daily, N = 3 (7.1%); levetirac-
etam 4000 mg daily, N = 4 (10.5%). None of these
was considered by the investigator to be related to
drug treatment. Nine patients reported serious adverse
events during the open-label period when receiving
4000 mg daily of levetiracetam. They had been ran-
domized during the double-blind period to placebo,
N = 5 (17.2%); levetiracetam 2000 mg daily, N = 3
(10.7%); and levetiracetam 4000 mg daily, N = 1
(3.4%). Three patients had serious adverse events dur-
ing the open-label period that were considered to be
related to levetiracetam (convulsion in two patients
and hallucination in one patient). Three patients re-
ported serious adverse events during the placebo run-
out/downtitration period.
There were no significant changes in clinical labora-
tory parameters nor in any physical or neurological ex-
amination among the three treatment groups through-
out the study. No changes were observed in concomi-
tant antiepileptic trough drug concentrations.
Efficacy
Double-blind treatment period. A total of 86 patients
completed 24 weeks of double-blind treatment and
had adequate seizure data at both baseline and week 24
for efficacy assessment. After 24 weeks of treatment,
the responder rate of the inferential intention-to-
treat population (N = 86) was 48.1% (13/27) and
28.6% (8/28) in patients treated with levetiracetam
2000 mg and 4000 mg daily, respectively, compared
with placebo (16.1%, 5/31) (Fig. 4). The difference
in response was statistically significant between the
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Fig. 3: The percentage of patients discontinuing within
28 days of double-blind treatment in comparison with the
total percentage of discontinuations during the double-blind
period. Differences vs. placebo were not significant. AE =
adverse event; LEV = levetiracetam.
2000 mg daily treatment group and placebo (P =
0.01). After 24 weeks, the odds of obtaining a reduc-
tion in seizure frequency of ≥50% with levetiracetam
2000 mg and 4000 mg daily were 4.9 (95% confi-
dence interval [CI]: 1.4; 16.8) and 2.0 (95% CI:0.6;
7.2) higher than the odds of obtaining the same re-
sponse with placebo, respectively. Responder rates af-
ter 4 weeks of double-blind treatment were consistent
with the 24-week findings. Differences in responder
rates were statistically significant between the leve-
tiracetam 2000 mg daily treatment group and placebo,
44.1% vs. 19.4%, respectively, (P < 0.05). The re-
sponder rate in patients who received 4000 mg daily
of levetiracetam was 33.3%.
For all seizure types, an overall reduction in me-
dian seizure frequency was observed for the levetirac-
etam treatment groups compared with baseline. Me-
dian seizure frequency was 0.62 and 0.59 per week
with levetiracetam 2000 mg and 4000 mg daily, re-
spectively (1.21 and 1.34 at baseline, respectively). In
contrast, median seizure frequency increased for pa-
tients who received placebo (1.40 vs. 1.24 at base-
line). In the levetiracetam treatment groups, the me-
dian percentage reductions in seizure frequency were
similar between seizure types I and II, and were higher
when compared with placebo, although differences
were not significant (Fig. 5). Throughout the entire
double-blind treatment period, seven patients were
completely seizure free; of these, four patients had re-
ceived 2000 mg daily, two received 4000 mg daily of
levetiracetam, and one received placebo.
Open-label treatment period In the open-label treat-
ment period, all treatment groups received 4000 mg
daily of levetiracetam, except for five patients
(placebo, N = 1; levetiracetam 2000 mg daily, N =
4) who continued with their double-blind treatment
because they were seizure free throughout the double-
blind period. Overall, according to analysis using the
last available observation under treatment, 43% of the
79 patients had a≥50% reduction in seizure frequency
following open-label treatment compared with base-
line. The percentage of responders was 44.0% in pa-
tients initially treated with placebo, 46.2% in patients
initially treated with levetiracetam 2000 mg daily, and
39.3% in patients initially treated with levetiracetam
4000 mg daily (Fig. 4). Importantly, an increase in
response was observed in patients who had received
placebo in the double-blind treatment period but were
subsequently switched to treatment with 4000 mg
daily of levetiracetam in the open-label treatment pe-
riod (response rose from 16.7% to 44.0% [11/25], re-
spectively). The responder rate of patients switched
from 2000 mg to 4000 mg daily of levetiracetam was
similar (46%; 12/26).
DISCUSSION
Results of this placebo-controlled study demonstrate
that levetiracetam was well tolerated at doses of
2000 mg and 4000 mg daily without titration in pa-
tients with refractory epilepsy. The most frequent ad-
verse effects were somnolence and asthenia. Somno-
lence was most often cited as the reason for study dis-
continuation. In this study, the occurrence of somno-
lence was more pronounced at the initiation of treat-
ment with levetiracetam and with the higher dose. This
study supports pre-clinical findings6–8 by demonstrat-
ing that levetiracetam could have a broad-spectrum
potential because it decreased the frequency of par-
tial and secondarily and primary generalized seizures.
Specific studies in generalized seizures are ongoing.
A clinical response was achieved early in the course
of treatment. Responder rates after 4 and 24 weeks
were similar. Throughout the double-blind treatment
period, four patients receiving levetiracetam 2000 mg
daily and two receiving 4000 mg daily of levetirac-
etam remained seizure free compared with the one re-
ceiving placebo.
Levetiracetam has been evaluated in three other
larger clinical trials at doses ranging from 1000 mg
to 3000 mg daily12. Based on pooled efficacy data,
at all doses tested (1000 mg, 2000 mg, and 3000 mg
daily) levetiracetam was more effective than placebo
in reducing the weekly partial seizure frequency12.
A distinct dose–response relationship was observed,
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with responder rates of 27.7%, 31.6%, and 41.3% for
the 1000 mg, 2000 mg, and 3000 mg daily doses, re-
spectively. In the present study, efficacy was higher
with levetiracetam 2000 mg daily than 4000 mg daily,
with responder rates of 48.1% and 28.6%. When pa-
tients receiving 2000 mg daily were switched to the
higher 4000 mg daily dose in the open-label period,
no additional efficacy was gained and the incidence
of somnolence was higher at the higher dose. Based
on these results, levetiracetam may have a therapeutic
window with optimal response achieved at 3000 mg
daily. However, the present study was not powered
to detect a significant difference between the leve-
tiracetam treatment arms. The study population was
small and there was an overall low baseline seizure
frequency. In addition, the study consisted of a short
4-week baseline period. Results should therefore be
interpreted with care, and no firm conclusions can be
made about efficacy.
CONCLUSIONS
Levetiracetam can be safely initiated at high therapeu-
tic doses from 2000–4000 mg daily and has broad-
spectrum potential. The higher dose may be used, pos-
sibly at the expense of an increased incidence of som-
nolence, but it is not necessarily more effective than
the lower one, suggesting a therapeutic window of ef-
ficacy. Seizure control is rapidly achieved without the
need for titration. Although not likely to be the general
recommendation for use, this represents an advantage
over other antiepileptic drugs in terms of ease of use
in clinical practice.
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